Aktien Sensor

Veeva Systems has formed a strategic partnership with Grünenthal to streamline regulatory processes and accelerate the delivery of life-saving medicines to patients.

Philips is poised to capitalize on the shifting healthcare landscape, driven by a surge in demand for cutting-edge solutions due to an aging population and technological advancements.

Regeneron Pharmaceuticals has made significant strides with the launch of a donation matching program and FDA approval for Dupixent to treat bullous pemphigoid, solidifying its position as a leader in the pharmaceutical industry.

Gilead Sciences has made significant announcements, including a partnership to develop a novel cancer treatment, solidifying its position as a leader in innovative biopharmaceuticals.

Recordati Industria Chimica e Farmaceutica SpA has secured an exclusive licensing deal with Amarin to commercialize cardiovascular medicine Vazkepa in 59 European countries, marking a significant milestone for the company’s growth.

Centene Corp’s stock price may be stagnant, but the company is poised for growth as health insurers simplify prior authorization requests, a move that could boost customer satisfaction and loyalty.

Teva Pharmaceutical Industries Ltd has announced positive results from studies on its migraine prevention treatment, AJOVY, showing sustained effectiveness and a favorable safety profile over two years.

EssilorLuxottica’s stock price has taken a significant tumble, but despite a 10% year-over-year revenue growth and 15% year-over-year net income increase, investors are left wondering what’s behind the sudden downturn.

Chugai Pharmaceutical Co Ltd’s stock price has experienced a moderate decline, but the company’s long-term prospects remain strong due to its innovative research and strategic partnerships.

Hologic’s stock has declined to a 52-week low of $51.90, with a premium valuation indicated by a price-to-earnings ratio of 27.01.